Global Urological Cancer Therapeutics Drugs Market 2021-2026
- Published Date: 2021-05-17
- Report ID: 116806
- Pages: 180
-
Format:
Prudent Markets Predicts that Urological Cancer Therapeutics Drugs Market was valued USD xxxx unit in 2020 and is expected to reach USD xxxx Unit by the year 2025, growing at a CAGR of xx% globally.
Global Urological Cancer Therapeutics Drugs Market Overview:
Global Urological Cancer Therapeutics Drugs Market Report 2020 comes with the extensive industry analysis of development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2020-2025.This research study of Urological Cancer Therapeutics Drugs involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Impact of COVID-19 on Urological Cancer Therapeutics Drugs Market
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affected the Urological Cancer Therapeutics Drugs market in 2020.
Global Urological Cancer Therapeutics Drugs Market Segmentation
By Type, Urological Cancer Therapeutics Drugs market has been segmented into:
Xofigo (radium Ra 223 dichloride)
Jevtana (cabazitaxel)
Inlyta (axitinib)
Votrient (pazopanib hydrochloride)
Sutent (sunitinib malate)
Zytiga (abiraterone acetate)
Xtandi (enzalutamide)
Opdivo (nivolumab)
Provenge (sipuleucel-T)
By Application, Urological Cancer Therapeutics Drugs market has been segmented into:
Hospital
Medical Research Laboratory
Others
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain etc.)
Asia-Pacific (China, India, Japan, Southeast Asia etc.)
South America (Brazil, Argentina etc.)
Middle East & Africa (Saudi Arabia, South Africa etc.)
Top Key Players Covered in Urological Cancer Therapeutics Drugs market are:
Novartis
Pfizer
Johnson & Johnson
AstraZeneca
Astellas
Bristol-Myers Squibb
Abbott Laboratories
Celgene Corporation
Dendreon Corporation
Ferring Pharmaceuticals
GlaxoSmithKline plc
Indevus Pharmaceuticals Inc
Ipsen
Roche Healthcare
Sanofi S.A.
1. Market Overview of Urological Cancer Therapeutics Drugs
1.1 Urological Cancer Therapeutics Drugs Market Overview
1.1.1 Urological Cancer Therapeutics Drugs Product Scope
1.1.2 Market Status and Outlook
1.2 Urological Cancer Therapeutics Drugs Market Size by Regions: 2015 VS 2021 VS 2026
1.3 Urological Cancer Therapeutics Drugs Historic Market Size by Regions (2015-2020)
1.4 Urological Cancer Therapeutics Drugs Forecasted Market Size by Regions (2021-2026)
1.5 Covid-19 Impact on Key Regions, Keyword Market Size YoY Growth (2015-2026)
1.5.1 North America
1.5.2 East Asia
1.5.3 Europe
1.5.4 South Asia
1.5.5 Southeast Asia
1.5.6 Middle East
1.5.7 Africa
1.5.8 Oceania
1.5.9 South America
1.5.10 Rest of the World
1.6 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.6.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.6.2 Covid-19 Impact: Commodity Prices Indices
1.6.3 Covid-19 Impact: Global Major Government Policy
2. Covid-19 Impact Urological Cancer Therapeutics Drugs Sales Market by Type (2015-2026)
2.1 Global Urological Cancer Therapeutics Drugs Historic Market Size by Type (2015-2020)
2.2 Global Urological Cancer Therapeutics Drugs Forecasted Market Size by Type (2021-2026)
2.3 Xofigo (radium Ra 223 dichloride)
2.4 Jevtana (cabazitaxel)
2.5 Inlyta (axitinib)
2.6 Votrient (pazopanib hydrochloride)
2.7 Sutent (sunitinib malate)
2.8 Zytiga (abiraterone acetate)
2.9 Xtandi (enzalutamide)
2.10 Opdivo (nivolumab)
2.11 Provenge (sipuleucel-T)
3. Covid-19 Impact Urological Cancer Therapeutics Drugs Sales Market by Application (2015-2026)
3.1 Global Urological Cancer Therapeutics Drugs Historic Market Size by Application (2015-2020)
3.2 Global Urological Cancer Therapeutics Drugs Forecasted Market Size by Application (2021-2026)
3.3 Hospital
3.4 Medical Research Laboratory
3.5 Others
4. Covid-19 Impact Market Competition by Manufacturers
4.1 Global Urological Cancer Therapeutics Drugs Production Capacity Market Share by Manufacturers (2015-2020)
4.2 Global Urological Cancer Therapeutics Drugs Revenue Market Share by Manufacturers (2015-2020)
4.3 Global Urological Cancer Therapeutics Drugs Average Price by Manufacturers (2015-2020)
5. Company Profiles and Key Figures in Urological Cancer Therapeutics Drugs Business
5.1 Novartis
5.1.1 Novartis Company Profile
5.1.2 Novartis Urological Cancer Therapeutics Drugs Product Specification
5.1.3 Novartis Urological Cancer Therapeutics Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.2 Pfizer
5.2.1 Pfizer Company Profile
5.2.2 Pfizer Urological Cancer Therapeutics Drugs Product Specification
5.2.3 Pfizer Urological Cancer Therapeutics Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.3 Johnson & Johnson
5.3.1 Johnson & Johnson Company Profile
5.3.2 Johnson & Johnson Urological Cancer Therapeutics Drugs Product Specification
5.3.3 Johnson & Johnson Urological Cancer Therapeutics Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.4 AstraZeneca
5.4.1 AstraZeneca Company Profile
5.4.2 AstraZeneca Urological Cancer Therapeutics Drugs Product Specification
5.4.3 AstraZeneca Urological Cancer Therapeutics Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.5 Astellas
5.5.1 Astellas Company Profile
5.5.2 Astellas Urological Cancer Therapeutics Drugs Product Specification
5.5.3 Astellas Urological Cancer Therapeutics Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.6 Bristol-Myers Squibb
5.6.1 Bristol-Myers Squibb Company Profile
5.6.2 Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Product Specification
5.6.3 Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.7 Abbott Laboratories
5.7.1 Abbott Laboratories Company Profile
5.7.2 Abbott Laboratories Urological Cancer Therapeutics Drugs Product Specification
5.7.3 Abbott Laboratories Urological Cancer Therapeutics Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.8 Celgene Corporation
5.8.1 Celgene Corporation Company Profile
5.8.2 Celgene Corporation Urological Cancer Therapeutics Drugs Product Specification
5.8.3 Celgene Corporation Urological Cancer Therapeutics Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.9 Dendreon Corporation
5.9.1 Dendreon Corporation Company Profile
5.9.2 Dendreon Corporation Urological Cancer Therapeutics Drugs Product Specification
5.9.3 Dendreon Corporation Urological Cancer Therapeutics Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.10 Ferring Pharmaceuticals
5.10.1 Ferring Pharmaceuticals Company Profile
5.10.2 Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Product Specification
5.10.3 Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.11 GlaxoSmithKline plc
5.11.1 GlaxoSmithKline plc Company Profile
5.11.2 GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Product Specification
5.11.3 GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.12 Indevus Pharmaceuticals Inc
5.12.1 Indevus Pharmaceuticals Inc Company Profile
5.12.2 Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Product Specification
5.12.3 Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.13 Ipsen
5.13.1 Ipsen Company Profile
5.13.2 Ipsen Urological Cancer Therapeutics Drugs Product Specification
5.13.3 Ipsen Urological Cancer Therapeutics Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.14 Roche Healthcare
5.14.1 Roche Healthcare Company Profile
5.14.2 Roche Healthcare Urological Cancer Therapeutics Drugs Product Specification
5.14.3 Roche Healthcare Urological Cancer Therapeutics Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.15 Sanofi S.A.
5.15.1 Sanofi S.A. Company Profile
5.15.2 Sanofi S.A. Urological Cancer Therapeutics Drugs Product Specification
5.15.3 Sanofi S.A. Urological Cancer Therapeutics Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
6. North America
6.1 North America Urological Cancer Therapeutics Drugs Market Size (2015-2026)
6.2 North America Urological Cancer Therapeutics Drugs Key Players in North America (2015-2020)
6.3 North America Urological Cancer Therapeutics Drugs Market Size by Type (2015-2020)
6.4 North America Urological Cancer Therapeutics Drugs Market Size by Application (2015-2020)
7. East Asia
7.1 East Asia Urological Cancer Therapeutics Drugs Market Size (2015-2026)
7.2 East Asia Urological Cancer Therapeutics Drugs Key Players in North America (2015-2020)
7.3 East Asia Urological Cancer Therapeutics Drugs Market Size by Type (2015-2020)
7.4 East Asia Urological Cancer Therapeutics Drugs Market Size by Application (2015-2020)
8. Europe
8.1 Europe Urological Cancer Therapeutics Drugs Market Size (2015-2026)
8.2 Europe Urological Cancer Therapeutics Drugs Key Players in North America (2015-2020)
8.3 Europe Urological Cancer Therapeutics Drugs Market Size by Type (2015-2020)
8.4 Europe Urological Cancer Therapeutics Drugs Market Size by Application (2015-2020)
9. South Asia
9.1 South Asia Urological Cancer Therapeutics Drugs Market Size (2015-2026)
9.2 South Asia Urological Cancer Therapeutics Drugs Key Players in North America (2015-2020)
9.3 South Asia Urological Cancer Therapeutics Drugs Market Size by Type (2015-2020)
9.4 South Asia Urological Cancer Therapeutics Drugs Market Size by Application (2015-2020)
10. Southeast Asia
10.1 Southeast Asia Urological Cancer Therapeutics Drugs Market Size (2015-2026)
10.2 Southeast Asia Urological Cancer Therapeutics Drugs Key Players in North America (2015-2020)
10.3 Southeast Asia Urological Cancer Therapeutics Drugs Market Size by Type (2015-2020)
10.4 Southeast Asia Urological Cancer Therapeutics Drugs Market Size by Application (2015-2020)
11. Middle East
11.1 Middle East Urological Cancer Therapeutics Drugs Market Size (2015-2026)
11.2 Middle East Urological Cancer Therapeutics Drugs Key Players in North America (2015-2020)
11.3 Middle East Urological Cancer Therapeutics Drugs Market Size by Type (2015-2020)
11.4 Middle East Urological Cancer Therapeutics Drugs Market Size by Application (2015-2020)
12. Africa
12.1 Africa Urological Cancer Therapeutics Drugs Market Size (2015-2026)
12.2 Africa Urological Cancer Therapeutics Drugs Key Players in North America (2015-2020)
12.3 Africa Urological Cancer Therapeutics Drugs Market Size by Type (2015-2020)
12.4 Africa Urological Cancer Therapeutics Drugs Market Size by Application (2015-2020)
13. Oceania
13.1 Oceania Urological Cancer Therapeutics Drugs Market Size (2015-2026)
13.2 Oceania Urological Cancer Therapeutics Drugs Key Players in North America (2015-2020)
13.3 Oceania Urological Cancer Therapeutics Drugs Market Size by Type (2015-2020)
13.4 Oceania Urological Cancer Therapeutics Drugs Market Size by Application (2015-2020)
14. South America
14.1 South America Urological Cancer Therapeutics Drugs Market Size (2015-2026)
14.2 South America Urological Cancer Therapeutics Drugs Key Players in North America (2015-2020)
14.3 South America Urological Cancer Therapeutics Drugs Market Size by Type (2015-2020)
14.4 South America Urological Cancer Therapeutics Drugs Market Size by Application (2015-2020)
15. Rest of the World
15.1 Rest of the World Urological Cancer Therapeutics Drugs Market Size (2015-2026)
15.2 Rest of the World Urological Cancer Therapeutics Drugs Key Players in North America (2015-2020)
15.3 Rest of the World Urological Cancer Therapeutics Drugs Market Size by Type (2015-2020)
15.4 Rest of the World Urological Cancer Therapeutics Drugs Market Size by Application (2015-2020)
16 Urological Cancer Therapeutics Drugs Market Dynamics
16.1 Covid-19 Impact Market Top Trends
16.2 Covid-19 Impact Market Drivers
16.3 Covid-19 Impact Market Challenges
16.4 Porters Five Forces Analysis
18 Regulatory Information
17 Analyst's Viewpoints/Conclusions
18 Appendix
18.1 Research Methodology
18.1.1 Methodology/Research Approach
18.1.2 Data Source
18.2 Disclaimer
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
